Yesterday, Sanofi India received marketing approval for its new diabetes drug – Soliqua (in a pre-filled pen), from the Central Drugs Standard Control Organization (CDSCO).
Soliqua can improve glycemic control when used along with appropriate dietary measures and exercise regime adherence. The drug is indicated for treating type 2 diabetes (T2D) in obese adults who do not benefit from oral or injectable therapies.
Soliqua is to be dispensed once daily and is formulated as a fixed-ratio combination in pre-filled pens – 10-40 and 30-60 of insulin glargine and lixisenatide. This formulation is projected to enable customized solutions for obese adults with suboptimal glycemic control.
Its constituents are – insulin glargine (long-acting basal insulin) 100 Units/ml and lixisenatide, a glucagon-like peptide-1 receptor agonist (GLP-1-RA).
The global Solimix study confirmed weight benefits and lower hypoglycemia rates with Soliqua than with premixed insulin. Further, its once-daily dosage, as opposed to twice daily dosing requirement with premised insulin, offers a valuable alternative for physicians and endocrinologists.
Subscribe To Our Newsletter
Filter out the noise and nurture your inbox with health and wellness advice that's inclusive and rooted in medical expertise.
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks